Although both MDSC populations would ideally decrease with effective immunomodulatory anti-cancer therapy, it is encouraging that OPN5 directly impacts M-MDSCs—an aggressively immune-suppressive MDSC population linked to negative outcomes in patients with CLL [10–12,32]. This evidence concerns the gene OPN5 and B-cell chronic lymphocytic leukemia.